Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Mercy Children's Hospital
mi
from
Toledo, OH
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Mercy Children's Hospital
mi
from
Toledo, OH
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Saint Francis Children's Hospital
mi
from
Tulsa, OK
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Saint Francis Children's Hospital
mi
from
Tulsa, OK
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Greenville Memorial Hospital
mi
from
Greenville, SC
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Greenville Memorial Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Sanford Children's Hospital
mi
from
Sioux Falls, SD
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Sanford Children's Hospital
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Children's Corporate Center, Division of Neonatology
mi
from
Wauwatosa, WI
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Children's Corporate Center, Division of Neonatology
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
University of Calgary
mi
from
Calgary,
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Jersey Shore University Medical Center
mi
from
Neptune City, NJ
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Jersey Shore University Medical Center
mi
from
Neptune City, NJ
Click here to add this to my saved trials
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated:  10/30/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants
Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants Requiring Mechanical Ventilation or Positive Pressure Support on Days 5-14 After Birth
Status: Enrolling
Updated: 10/30/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Emory University
mi
from
Atlanta, GA
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of Kentucky
mi
from
Lexington, KY
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Tulane University
mi
from
New Orleans, LA
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Tulane University
mi
from
New Orleans, LA
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Cornell University
mi
from
New York, NY
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of Oregon
mi
from
Portland, OR
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of Oregon
mi
from
Portland, OR
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Hemophilia Center of Western Pennsylvania
mi
from
Pittsburgh, PA
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Hemophilia Center of Western Pennsylvania
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
North Texas Comprehensive Hemophilia Center
mi
from
Dallas, TX
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
North Texas Comprehensive Hemophilia Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Baylor College of Medicine
mi
from
Houston, TX
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Intermountain Hemophilia and Thrombosis Center
mi
from
Salt Lake City, UT
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Intermountain Hemophilia and Thrombosis Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated:  10/30/2017
Medical University of Vienna
mi
from
Vienna,
Hemophilia Inhibitor Previously Untreated Patient Study
Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia
Status: Enrolling
Updated: 10/30/2017
Medical University of Vienna
mi
from
Vienna,
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Ohio State University
mi
from
Columbus, OH
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Oregon Health and Science University
mi
from
Portland, OR
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  10/30/2017
Local Institution
mi
from
Pamplona,
A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 10/30/2017
Local Institution
mi
from
Pamplona,
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Emory University
mi
from
Atlanta, GA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Indianda Spine Group
mi
from
Indianapolis, IN
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Indianda Spine Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Kansas University Medical Center
mi
from
Kansas City, KA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
John Hopkins University
mi
from
Baltimore, MD
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
John Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
New England Baptist Hospital
mi
from
Boston, MA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
New England Baptist Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Thomas Jefferson University and Rothman Institure Orthopaedics
mi
from
Philadelphia, PA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Thomas Jefferson University and Rothman Institure Orthopaedics
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Universty of Utah
mi
from
Salt Lake City, UT
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Universty of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
University of Virginia
mi
from
Charlottesville, VA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Harborview Medical Center
mi
from
Seattle, WA
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
University of Toronto
mi
from
Toronto,
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
University of Toronto
mi
from
Toronto,
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
Spine Education Research Institute
mi
from
Thornton, CO
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
Spine Education Research Institute
mi
from
Thornton, CO
Click here to add this to my saved trials
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated:  10/30/2017
The Mayo Clinic
mi
from
Rochester, MN
Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
An Assessment of Surgical Techniques for Treating Cervical Spondylotic Myelopathy
Status: Enrolling
Updated: 10/30/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
TRADE-Testosterone Replacement and Dutasteride Effectiveness
Testosterone Replacement and Dutasteride Effectiveness (TRADE)
Status: Enrolling
Updated:  10/30/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
TRADE-Testosterone Replacement and Dutasteride Effectiveness
Testosterone Replacement and Dutasteride Effectiveness (TRADE)
Status: Enrolling
Updated: 10/30/2017
VA Puget Sound Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
Phase I/II Study of Myeloablative Allogeneic Stem Cell Transplantation for Aggressive Hematologic Malignancies Using Clofarabine and Busulfan x 4 (Clo/BU4) Regimen
Status: Enrolling
Updated:  10/30/2017
University of Michigan, Department of Internal Medicine, Blood and Marrow Transplant Program
mi
from
Ann Arbor, MI
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
Phase I/II Study of Myeloablative Allogeneic Stem Cell Transplantation for Aggressive Hematologic Malignancies Using Clofarabine and Busulfan x 4 (Clo/BU4) Regimen
Status: Enrolling
Updated: 10/30/2017
University of Michigan, Department of Internal Medicine, Blood and Marrow Transplant Program
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/1/2017
Clinical Research Facility
mi
from
Stony Brook, NY
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/1/2017
Clinical Research Facility
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/1/2017
Clinical Research Facility
mi
from
Cleveland, OH
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/1/2017
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/1/2017
Clinical Research Facility
mi
from
Houston, TX
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/1/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials